News & Reports

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

MolecularMD Closes $6 Million Series B Financing and Announces Ensuing Growth Initiatives

Dan Snyder, President and COO of MolecularMD commented, “We are grateful for the continued support of Ballast Point Ventures, and we are pleased to be adding oncology-focused Nextech Invest to our investor group. We are well positioned to put the capital to work as we further define our presence in the high growth molecular diagnostics market. MolecularMD has over six years of proven performance, having provided testing in worldwide pivotal trials for several of the most successful targeted cancer therapies […]

July 9, 2012 |

New Report Shows Oregon Clinical Trials Benefit State’s Health and Economy

Working in collaboration with Oregon’s university medical schools, hospitals and clinical research centers, biopharmaceutical companies are conducting or have conducted since 1999 more than 2,300 clinical trials of new medicines in the state, a report released today shows.

Clinical trials are critical to the development of new medicines, accounting for up to seven years of the 10 to 15 years required to develop a new drug, according to “Research in Your Backyard: Pharmaceutical Clinical Trials in Oregon.”

The report – compiled by […]

Oregon Bioscience Association Announces Board Officers and Directors for 2012

FOR IMMEDIATE RELEASE – March 20, 2012

CONTACT: Dennis McNannay, Executive Director, Oregon Bioscience Assoc., (503) 548-4432
Dianne Danowski Smith, Oregon Bio board member, (503) 201-7019

OREGON BIOSCIENCE ASSOCIATION ANNOUNCES BOARD OFFICERS AND DIRECTORS FOR 2012

(Portland, Ore.) — Peter Murray, site executive and vice president for one of Oregon’s largest medical device manufacturers, Welch Allyn, has been appointed chairman of the Oregon Bioscience Association (Oregon Bio) board of directors. Executive committee members include Ryan Dunlap, treasurer, Moss Adams LLP; and Michael Phillips, secretary and […]

Broad Coalition Urges House of Representatives to Repeal Medical Device Tax

June 6, 2012

“We continue to believe that implementation of what was to be a $20 billion excise tax – and is now estimated to collect over $30 billion in taxes – will adversely impact patient care and innovation, and will substantially increase the costs of health care,” the letter states.The 2.3% medical device tax was passed as a part of the health care reform legislation in 2010, and the repeal bill is scheduled for a vote in the U.S. House […]

TREAT Act Offers Renewed Hope for Patients

Washington, DC (February 15, 2012) – Today, the Biotechnology Industry Organization (BIO) praised Sen. Kay Hagan (D-NC) for introducing the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act. The following statement can be attributed to BIO President and CEO Jim Greenwood:

“The Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act will help unleash the promise of biotechnology to speed life-saving cures, novel medicines and scientific breakthroughs to patients living with debilitating diseases such as cancer, […]

Continued Growth in Oregon’s Bioscience Industry Again Cited by International BIO

FOR IMMEDIATE RELEASE – July 5, 2012

CONTACT: Dennis McNannay, Executive Director, Oregon Bioscience Assoc., (503) 548-4432
Dianne Danowski Smith, Oregon Bio board member, (503) 201-7019

CONTINUED GROWTH IN OREGON’S BIOSCIENCE INDUSTRY AGAIN CITED BY INTERNATIONAL BIO

Oregon continues as a high growth state, gaining in employment, wages and establishments, according to the world’s leading organization for biotechnology and life sciences, the Biotechnology Industry Organization (BIO)

(Portland, Ore.) — After three years of a downward recessionary impact on the bioscience industry across the U.S., Oregon kept an overall positive […]

Head-to-head study shows a natrually occurring non-toxic spray by Tec Labs treats human head lice effectively when compared to the common pesticide formula

(Albany, Ore.)-  The surprising results of a new study1 show a safe, non-toxic solution, which is widely available over the counter, is effective at treating head lice infestations. A simple solution used by a growing number of consumers, shows the naturally occurring ingredient sodium chloride is safe for adults and children.

The preliminary study compared the results of applying sodium chloride versus permethrin, a synthetic insecticide. Many lice treatments use permethrin, which has been a standard lice treatment for decades. The […]

June 19, 2012 |

FEI Reports Record Revenue and EPS for the Fourth Quarter and 2011

FEI Reports Record Revenue and EPS for the Fourth Quarter and 2011

HILLSBORO, Ore., Feb. 8, 2012 (GLOBE NEWSWIRE) — FEI Company (Nasdaq:FEIC) reported record revenue and earnings for 2011 and for the fourth quarter. Revenue and earnings per share computed on the basis of accounting principles generally accepted in the United States (“GAAP”) were the highest of any quarter in the company’s history. Several items had an impact on the fourth quarter GAAP results, as detailed below and in the […]

February 27, 2012 |

Bend Research Signs License Agreement With Eli Lilly and Company

Bend Research Signs License Agreement With Eli Lilly and Company

Under the terms of the agreement, Bend Research will make its proprietary spray-dried dispersion (SDD) technology available to Lilly. This technology, which improves the bioavailability of compounds with low aqueous solubility, has been applied successfully to hundreds of compounds at various stages of development, from preclinical studies to Phase III clinical trials. Lilly formulators and scientists will also have broad access to Bend Research’s portfolio of other drug-delivery technologies.

In addition, as […]